Clinical significance of the LacdiNAc‐glycosylated prostate‐specific antigen assay for prostate cancer detection

To reduce unnecessary prostate biopsies (Pbx), better discrimination is needed. To identify clinically significant prostate cancer (CSPC) we determined the performance of LacdiNAc‐glycosylated prostate‐specific antigen (LDN‐PSA) and LDN‐PSA normalized by prostate volume (LDN‐PSAD). We retrospectivel...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Sci
Päätekijät: Yoneyama, Tohru, Tobisawa, Yuki, Kaneko, Tomonori, Kaya, Takatoshi, Hatakeyama, Shingo, Mori, Kazuyuki, Sutoh Yoneyama, Mihoko, Okubo, Teppei, Mitsuzuka, Koji, Duivenvoorden, Wilhelmina, Pinthus, Jehonathan H., Hashimoto, Yasuhiro, Ito, Akihiro, Koie, Takuya, Suda, Yoshihiko, Gardiner, Robert A., Ohyama, Chikara
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2019
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6676104/
https://ncbi.nlm.nih.gov/pubmed/31145522
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14082
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia